JP2020523319A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020523319A5 JP2020523319A5 JP2019567691A JP2019567691A JP2020523319A5 JP 2020523319 A5 JP2020523319 A5 JP 2020523319A5 JP 2019567691 A JP2019567691 A JP 2019567691A JP 2019567691 A JP2019567691 A JP 2019567691A JP 2020523319 A5 JP2020523319 A5 JP 2020523319A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence
- fibrosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 53
- 206010016654 Fibrosis Diseases 0.000 claims 10
- 230000004761 fibrosis Effects 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 102000009490 IgG Receptors Human genes 0.000 claims 4
- 108010073807 IgG Receptors Proteins 0.000 claims 4
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 4
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 230000002519 immonomodulatory effect Effects 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 101001039113 Homo sapiens Leucine-rich repeat-containing protein 15 Proteins 0.000 claims 2
- 102100040645 Leucine-rich repeat-containing protein 15 Human genes 0.000 claims 2
- 208000034189 Sclerosis Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000000651 myofibroblast Anatomy 0.000 claims 2
- 239000008196 pharmacological composition Substances 0.000 claims 2
- 210000004500 stellate cell Anatomy 0.000 claims 2
- 208000005748 Aggressive Fibromatosis Diseases 0.000 claims 1
- 102100024155 Cadherin-11 Human genes 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010059352 Desmoid tumour Diseases 0.000 claims 1
- 206010061431 Glial scar Diseases 0.000 claims 1
- 206010018341 Gliosis Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000024934 IgG4-related mediastinitis Diseases 0.000 claims 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000002805 Mediastinal fibrosis Diseases 0.000 claims 1
- 206010028594 Myocardial fibrosis Diseases 0.000 claims 1
- 206010036805 Progressive massive fibrosis Diseases 0.000 claims 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000001746 atrial effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 230000008602 contraction Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003352 fibrogenic effect Effects 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 108010000953 osteoblast cadherin Proteins 0.000 claims 1
- 210000000557 podocyte Anatomy 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 210000002435 tendon Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762516638P | 2017-06-07 | 2017-06-07 | |
| US62/516,638 | 2017-06-07 | ||
| PCT/US2018/036554 WO2018227018A1 (en) | 2017-06-07 | 2018-06-07 | Antibody conjugates of immune-modulatory compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020523319A JP2020523319A (ja) | 2020-08-06 |
| JP2020523319A5 true JP2020523319A5 (enExample) | 2021-07-26 |
Family
ID=64567206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019567691A Pending JP2020523319A (ja) | 2017-06-07 | 2018-06-07 | 免疫調節化合物の抗体コンジュゲートおよびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200199247A1 (enExample) |
| EP (1) | EP3634485A4 (enExample) |
| JP (1) | JP2020523319A (enExample) |
| CN (1) | CN110891605A (enExample) |
| AU (1) | AU2018279105A1 (enExample) |
| CA (1) | CA3065852A1 (enExample) |
| WO (1) | WO2018227018A1 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11583593B2 (en) | 2016-01-14 | 2023-02-21 | Synthis Therapeutics, Inc. | Antibody-ALK5 inhibitor conjugates and their uses |
| IL263616B2 (en) | 2016-07-07 | 2025-01-01 | Univ Leland Stanford Junior | Antibody-adjuvant conjugates |
| MX2019013517A (es) | 2017-05-24 | 2020-08-17 | Pandion Operations Inc | Inmunotolerancia dirigida. |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| CA3101181A1 (en) * | 2018-05-25 | 2019-11-28 | Silverback Therapeutics, Inc. | Amino-pyrazinecarboxamide compounds, conjugates, and uses thereof |
| CN111018857B (zh) * | 2018-10-09 | 2023-06-02 | 嘉兴优博生物技术有限公司 | 靶向蛋白酶降解平台(ted) |
| CR20210272A (es) | 2018-11-26 | 2021-07-14 | Forty Seven Inc | Anticuerpos humanizados contra c-kit |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| EP3725370A1 (en) * | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
| JP7682102B2 (ja) * | 2019-05-10 | 2025-05-23 | リビジェン バイオファーマ ホールディングス リミテッド | ヒト化抗ｃｄ１３７抗体およびその使用 |
| EP3972992A4 (en) | 2019-05-20 | 2023-07-19 | Pandion Operations, Inc. | MADCAM TARGETED IMMUNOTLERANCE |
| AU2020318112C1 (en) * | 2019-07-19 | 2024-09-26 | Wuxi Xdc Singapore Private Limited | Polypeptide complex for conjugation and use thereof |
| MX2022001321A (es) * | 2019-08-02 | 2022-05-20 | Akeso Pharmaceuticals Inc | Anticuerpo biespecifico anti-ctla4/anti-pd-1 y uso del mismo. |
| WO2021102332A1 (en) * | 2019-11-22 | 2021-05-27 | Silverback Therapeutics, Inc. | Tgfbetar2 inhibitor-lrrc15 antibody conjugates and uses thereof |
| CA3161573A1 (en) * | 2019-12-12 | 2021-06-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody-drug conjugates specific for cd276 and uses thereof |
| WO2021142086A1 (en) * | 2020-01-08 | 2021-07-15 | Synthis Therapeutics, Inc. | Alk5 inhibitor conjugates and uses thereof |
| TWI854088B (zh) * | 2020-01-27 | 2024-09-01 | 英商梅迪繆思有限公司 | 用於治療腎臟疾病之抗αｖβ８整聯蛋白抗體 |
| US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| KR20220161395A (ko) * | 2020-04-01 | 2022-12-06 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 중간엽 줄기 세포-유래된 암 세포 및 중간엽 줄기 세포 연관된 질환을 표적화하는 이뮤노테라노스틱 작용제 |
| CN113509557A (zh) * | 2020-04-09 | 2021-10-19 | 嘉兴优博生物技术有限公司 | 靶向蛋白酶降解平台(ted) |
| US20230174659A1 (en) * | 2020-05-14 | 2023-06-08 | The General Hospital Corporation | Agonistic tumor necrosis factor receptor superfamily polypeptides |
| US20230212282A1 (en) * | 2020-05-29 | 2023-07-06 | New York Society for the Relief of the Ruptured and Crippled, maintaining the Hospital for Special | Methods and compositions for treating, preventing the onset and/or slowing progression of osteoarthritis |
| EP4157883A4 (en) * | 2020-06-02 | 2024-12-04 | Children's Medical Center Corporation | NANOBODY CONJUGATES (VHH) AND THEIR USES |
| CN116209678A (zh) | 2020-07-01 | 2023-06-02 | 安尔士制药公司 | 抗asgr1抗体缀合物及其用途 |
| KR102506295B1 (ko) * | 2020-08-28 | 2023-03-08 | 국립암센터 | 디그옥시제닌에 대한 인간화 항체 및 이의 용도 |
| CN114146095A (zh) * | 2020-09-07 | 2022-03-08 | 是光隽恒(北京)生物科技有限公司 | 用于组织损伤修复的组合物及其制备方法和用途 |
| JP2023541853A (ja) * | 2020-09-08 | 2023-10-04 | ユーティレックス カンパニー リミテッド | Ｐｄ－１ポリペプチド変異体 |
| WO2022109105A1 (en) * | 2020-11-18 | 2022-05-27 | Pandion Operations, Inc. | Madcam targeted therapeutics and uses thereof |
| WO2022217022A1 (en) | 2021-04-10 | 2022-10-13 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
| CN117203238A (zh) | 2021-04-23 | 2023-12-08 | 普方生物制药美国公司 | Cd70结合剂、其偶联物及其使用方法 |
| JP2024526259A (ja) | 2021-07-02 | 2024-07-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗ｐｒｏｔａｃ抗体および複合体 |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| EP4444759A4 (en) * | 2021-12-09 | 2025-11-26 | Genequantum Healthcare Suzhou Co Ltd | ANTIBODY-CYTOKINE FUSION PROTEINS AND THEIR APPLICATIONS |
| WO2023125121A1 (zh) * | 2021-12-30 | 2023-07-06 | 四川科伦博泰生物医药股份有限公司 | 一类三并环化合物、其制备方法及用途 |
| JP2025530110A (ja) * | 2022-09-20 | 2025-09-11 | カーラス・バイオロジクス・ピーティーワイ・リミテッド | 二重特異性ポリペプチド及びその使用 |
| TW202432187A (zh) * | 2022-12-23 | 2024-08-16 | 美商建南德克公司 | 小腦蛋白降解劑結合物及其用途 |
| EP4642482A1 (en) | 2022-12-27 | 2025-11-05 | Merck Patent GmbH | Vhh anti-protac antibodies and complexes |
| FR3147278A1 (fr) * | 2023-03-31 | 2024-10-04 | Avacta Life Sciences Limited | Polypeptides de liaison au tnfr2 et procedes d'utilisation |
| FR3147292A1 (fr) * | 2023-03-31 | 2024-10-04 | Affyxell Therapeutics Co., Ltd. | Cellules genetiquement modifiees dans lesquelles un acide nucleique codant pour des variantes de la proteine stefine a se liant specifiquement au tnfr2 ou une proteine de fusion comprenant celle-ci a ete introduite, et leurs utilisations |
| WO2024200987A1 (en) * | 2023-03-31 | 2024-10-03 | Avacta Life Sciences Limited | Tnfr2 binding polypeptides and methods of use |
| TW202500195A (zh) * | 2023-05-18 | 2025-01-01 | 美商飛爾富來生物公司 | 異吲哚啉酮－戊二醯亞胺抗體結合物及其用途 |
| WO2024243545A1 (en) * | 2023-05-24 | 2024-11-28 | President And Fellows Of Harvard College | Compositions targeting endothelial cells and uses thereof |
| AR133955A1 (es) | 2023-09-26 | 2025-11-19 | Profoundbio Us Co | Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos |
| WO2025149661A1 (en) | 2024-01-10 | 2025-07-17 | Genmab A/S | Slitrk6 binding agents, conjugates thereof and methods of using the same |
| WO2025163120A1 (en) * | 2024-02-01 | 2025-08-07 | Adcytherix Sas | ANTIBODY-DRUG CONJUGATES COMPRISING AN ANTI-INTEGRIN ΑVβ6 BINDING ANTIBODY |
| EP4595981A1 (en) * | 2024-02-01 | 2025-08-06 | Jack Elands | Antibody-drug conjugates comprising an anti-integrin v 6 binding antibody |
| WO2025181219A1 (en) | 2024-02-29 | 2025-09-04 | Genmab A/S | Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same |
| WO2025216667A1 (en) * | 2024-04-12 | 2025-10-16 | Joint Stock Company «Biocad» | Monoclonal antibody that specifically binds to bdca-2 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2579805T3 (es) * | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| WO2006062779A2 (en) * | 2004-12-09 | 2006-06-15 | Centocor, Inc. | Anti-integrin immunoconjugates, methods and uses |
| CA2776037A1 (en) * | 2009-10-02 | 2011-04-07 | Ludwig Institute For Cancer Research Ltd | Anti-fibroblast activation protein antibodies and methods and uses thereof |
| WO2011040973A2 (en) * | 2009-10-02 | 2011-04-07 | Ludwig Institute For Cancer Research Ltd. | Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof |
| EP2608804A4 (en) * | 2010-08-27 | 2015-03-11 | Univ Miami | TREATMENT OF KIDNEY DISEASES |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| KR102438072B1 (ko) * | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| US9421594B2 (en) * | 2012-01-26 | 2016-08-23 | Yorozu Corporation | Method for manufacturing curved hollow pipe |
| JP6517240B2 (ja) * | 2014-05-22 | 2019-05-22 | シントン・バイオファーマシューティカルズ・ビー．ブイ．Ｓｙｎｔｈｏｎ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｂ．Ｖ． | 抗体へのリンカー薬物の部位特異的コンジュゲーションおよび得られるａｄｃ |
| AR105654A1 (es) * | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| US10195209B2 (en) * | 2015-11-30 | 2019-02-05 | Abbvie Inc. | Anti-huLRRC15 antibody drug conjugates and methods for their use |
| EP3383909B1 (en) * | 2015-11-30 | 2020-06-17 | AbbVie Inc. | Anti-human lrrc15 antibody drug conjugates and methods for their use |
| US20210154188A1 (en) * | 2018-04-02 | 2021-05-27 | Silverback Therapeutics, Inc. | Alk5 inhibitors, conjugates, and uses thereof |
| CA3101181A1 (en) * | 2018-05-25 | 2019-11-28 | Silverback Therapeutics, Inc. | Amino-pyrazinecarboxamide compounds, conjugates, and uses thereof |
-
2018
- 2018-06-07 JP JP2019567691A patent/JP2020523319A/ja active Pending
- 2018-06-07 WO PCT/US2018/036554 patent/WO2018227018A1/en not_active Ceased
- 2018-06-07 US US16/620,429 patent/US20200199247A1/en not_active Abandoned
- 2018-06-07 EP EP18813505.7A patent/EP3634485A4/en not_active Withdrawn
- 2018-06-07 CA CA3065852A patent/CA3065852A1/en not_active Abandoned
- 2018-06-07 CN CN201880047508.3A patent/CN110891605A/zh active Pending
- 2018-06-07 AU AU2018279105A patent/AU2018279105A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020523319A5 (enExample) | ||
| US20250346661A1 (en) | Dual specific antibodies | |
| FI3625259T3 (fi) | Anti-sirp-alfa vasta-aineet | |
| JP2019530434A5 (enExample) | ||
| JP2008521440A5 (enExample) | ||
| JP2019533719A5 (enExample) | ||
| JP2019502712A5 (enExample) | ||
| JP2019505527A5 (enExample) | ||
| JP2010517513A5 (enExample) | ||
| KR20220024729A (ko) | B-세포 성숙 항원을 표적으로 하는 다중특이성 항체에 대한 투여 요법 및 병용 요법 | |
| JP2015500207A5 (enExample) | ||
| RU2018129874A (ru) | Антитела против фактора свертывания xi | |
| JP2018517401A5 (enExample) | ||
| CN112469477A (zh) | 与成纤维细胞活化蛋白结合的异源二聚体抗体 | |
| JPWO2019129221A5 (enExample) | ||
| WO2013072523A4 (en) | Bi-specific antibodies for medical use | |
| CN110267990A (zh) | 结合共刺激性和检查点受体的双特异性免疫调节抗体 | |
| JP2013521252A5 (enExample) | ||
| JP2019528046A5 (enExample) | ||
| JP2024531419A (ja) | 線維性疾患の治療におけるアルファ－エノラーゼアンタゴニストの使用 | |
| JP2023076596A5 (enExample) | ||
| JPWO2021116337A5 (enExample) | ||
| JPWO2021042019A5 (enExample) | ||
| JPWO2019211665A5 (enExample) | ||
| JPWO2022097060A5 (enExample) |